Tag: Food and Drug Administration (FDA)

Skip to articles

The Food and Drug Administration (FDA or USFDA) is a federal agency of the United States Department of Health and Human Services, one of the United States federal executive departments. The FDA is responsible for protecting and promoting public health through the regulation and supervision of food safety, tobacco products, dietary supplements, prescription and over-the-counter pharmaceutical drugs (medications), vaccines, biopharmaceuticals, blood transfusions, medical devices, electromagnetic radiation emitting devices (ERED), cosmetics, animal foods & feed and veterinary products.

In June 1906, President Theodore Roosevelt signed into law the Food and Drug Act. The Act prohibited, under penalty of seizure of goods, the interstate transport of food that had been “adulterated.”

The responsibility for examining food and drugs for such “adulteration” or “misbranding” was given to the USDA Bureau of Chemistry. In 1927, the Bureau of Chemistry’s regulatory powers were reorganized under a new USDA body, the Food, Drug, and Insecticide organization. This name was shortened to the Food and Drug Administration (FDA) three years later.

The FDA was empowered by the United States Congress to enforce the Federal Food, Drug, and Cosmetic Act, which serves as the primary focus for the Agency; the FDA also enforces other laws, notably Section 361 of the Public Health Service Act and associated regulations, many of which are not directly related to food or drugs.

The FDA is most popularly known for its work in regulating the development of new drugs. Its powers related to clinical laboratories include the Clinical Laboratory Improvement Amendments (CLIA) that regulate laboratory testing and require clinical laboratories to be certificated by their state as well as the Center for Medicare and Medicaid Services (CMS) before they can accept human samples for diagnostic testing. Laboratories can obtain multiple types of CLIA certificates, based on the kinds of diagnostic tests they conduct.

The agency also has the authority to issue pre-market clearance of laboratory-developed tests (LDTs) for in vitro diagnostic instrument systems and IVD test kits that a laboratory wishes to sell to other labs. More recently, FDA has decided to launch the regulation of all LDTs, including pre-market review for higher-risk LDTs.

GE, UPMC Create Company for Digital Path Imaging

CEO SUMMARY: It’s a new joint venture with the potential to transform surgical pathology. General Electric Healthcare has extensive experience at supporting physicians’ work flow with digitized imaging systems, plus ample experience with molecular bio-markers. The University of Pittsburgh Medical Center’s pathology department is a world leader in whole-slide imaging and digitized pathology systems. Together,

View Article

Digitization of Pathology Is Making Steady Progress

CEO SUMMARY: Pathology digitization incorporates a greater scope of work-changing technologies than telepathology. It incorporates information technology, new diagnostic knowledge, and other engineering innovations to help pathologists move past glass and paper. Existing digital pathology systems are already helping pathologists reduce their travel from site to site by enabling them to view digitized images from

View Article

Roche, Digene, Centrex, Labtest.com, Specialty Labs, Tripath Imaging

ROCHE DIAGNOSTICS POSITIONED TO SERVE PUBLIC HEALTH LABS
HEIGHTENED CONCERNS over bioterrorist attacks have accelerated plans within the public health lab sector to acquire state-of-the art diagnostic technology in DNA typing and enzyme immunoassay.

Roche Diagnostics has instrument systems well-suited for both testing categories. Its DNA analyzers will compete with systems from Applied Biosystems and Cepheid. Major

View Article

AccuMed, AutoCyte, Cytyc, MorphoMetrix, Neuromedical, NeoPath

Automated Cytology Update
As predicted by THE DARK REPORT, the field of automated cytology has become a boiling pot, filled with controversy and change. Profits are meager. As we expected, the major issue revolves around the cost of this enhanced technology versus the measurable clinical benefits it delivers over traditional Pap smear procedures. Here’s a quick

View Article

AutoPap System Cleared For Primary Screening

CEO SUMMARY: It is time for pathologists and cytologists to buckle their safety belts. The marketplace for automated cytology is entering a new cycle of rapid change. NeoPath’s AutoPap System is now poised to demonstrate that it is economical and clinically viable. Expect continual improvements to automated cytology technology to eventually replace traditional methods of

View Article

Neuromedical’s PAPNET® Undergoing Enhancement

CEO SUMMARY: Financial pressures and a falling stock price impelled Neuromedical Systems, Inc. to revamp its sales and marketing plan for the PAPNET® System. During 1998, expect a new sales approach that supports a product with enhanced capabilities. Neuromedical is developing overseas markets while pursuing primary screening approval in the United States.

EXPECT TO SEE A

View Article